Journal profile · Medicine-Immunology and Allergy
Clinical & Translational Immunology
ISSN 2050-0068 · Wiley-Blackwell · United Kingdom
Clinical & Translational Immunology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.39; fully open access; APC about USD 3,380; median 136 days to acceptance (91 articles, last 24 months); acceptance rate 20% (journal website); 59 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical & Translational Immunology is published by Wiley-Blackwell and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Cell Function and Interaction, T-cell and B-cell Immunology and Immunotherapy and Immune Responses, together about 34.5% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical & Translational Immunology seeks to cover basic, translational and clinical studies in all aspects of human immunology, including experimental models specific to human diseases. Topics of particular interest within the journal’s scope include, but are not limited to, those listed below: cutting edge approaches including in vivo models of human disease that shed light on the mechanisms of immunity clinical studies with relevance to autoimmunity transplantation and tumor immunotherapy cutting edge immunoassays for monitoring clinical trials/patient responses infection and immunity - correlates of protection immunotherapies in relation to autoimmunity, primary and secondary immunodeficiencies, complement disorders and allergies pathogenesis and correlates of protection for autoimmune and endocrine disorders, infectious disease, malignancy and transplantation The journal publishes peer-reviewed Original Articles, Case Reports, Reviews,Theoretical Articles, Short Communications, and Special Features. In addition, Research Summaries are provided for selected articles. Editorial articles are brief comments written by the editor(s) of the journal or by guest editor(s) of Special Features based on the contents of the current issue or topical subjects that fall within the scope of the journal. Letters to the Editor present preliminary reports of unusual urgency, significance and interest, whose subjects may be republished in expanded form. Reviews can be submitted by authors without invitation but authors are encouraged to submit an abstract of the review to the Editorial Office (CTI@immunology.org.au) to consider for suitability prior to submission of a full article. Submissions of Review articles from outstanding graduate students are also encouraged under the following conditions: An abstract of the review should be submitted to the Editorial Office (CTI@immunology.org.au) to consider for suitability prior to the submission of a full article The student's supervisor who has most expertise in the area being reviewed must be a participatory co-author on the paper The article should encompass a critical assessment of an area: the timeliness of this assessment should be explicitly justified Abstracting and Indexing Information Biological Science Database (ProQuest) BIOSIS Previews (Clarivate Analytics) Embase (Elsevier) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) Hospital Premium Collection (ProQuest) Natural Science
From the journal's Aims & Scope
Research area (LetPub): Medicine-Immunology and Allergy
Editor-in-chief Seth MastersPublisher website
Editorial board by country: 3 in mainland China (about 9%); most named Australia 23, Mainland China 3, New Zealand 2, United Kingdom 1, India 1 (32 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Cell Function and InteractionImmunology and Microbiology14%
- T-cell and B-cell ImmunologyImmunology and Microbiology10.8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology9.8%
- Cancer Immunotherapy and BiomarkersMedicine7.3%
- CAR-T cell therapy researchMedicine7.1%
- SARS-CoV-2 and COVID-19 ResearchMedicine6.2%
- COVID-19 Clinical Research StudiesMedicine4.9%
- IL-33, ST2, and ILC PathwaysImmunology and Microbiology4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePubMedEmbasePublisher website
Other: ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.39LetPub ·
- Impact factor (publisher)
- 3.4Publisher website ·
- Impact factor (publisher) 2025
- 3.4Publisher website ·
- CiteScore 2026-06
- 7.2LetPub ·
- CiteScore (publisher)
- 7.2Publisher website ·
- CiteScore (publisher) 2025
- 7.2Publisher website ·
- SJR 2026-06
- 1.31LetPub ·
- SNIP 2026-06
- 0.82LetPub ·
- h-index
- 76OpenAlex ·
- i10-index
- 486OpenAlex ·
- 2-year mean citedness
- 2.96OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 45LetPub ·
- Articles per year (publisher) 2025
- 45Publisher website ·
- Downloads per year (publisher) 2025
- 269,749Publisher website ·
Articles by year OpenAlex count · 936 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 55 | 55 | 29 |
| 2025 | 59 | 59 | 114 |
| 2024 | 78 | 78 | 426 |
| 2023 | 61 | 61 | 554 |
| 2022 | 84 | 84 | 1,526 |
| 2021 | 143 | 143 | 3,715 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
136 daysMedian, submission to acceptance · P25–P75 93 days – 207 days
- Acceptance to online
- median 21 days (91 articles)
- Submission to online
- median 165 days
- Sample
- 91 articles with submission and acceptance dates (90 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Acceptance rate (publisher)
- 20%Publisher website ·
- Acceptance rate (publisher) 2025
- 20%Publisher website ·
- Submission to first decision
- 5 daysPublisher website ·
- Submission to first decision 2025
- 5 daysPublisher website ·
- Submission to acceptance 2025
- 146 daysPublisher website ·
- Acceptance to publication 2025
- 22 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,380 / GBP 2,580 / EUR 3,070 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,070 / EUR 2,790 / GBP 2,340 | — | — | |
| LetPub | USD 2,660 / GBP 2,030 / EUR 2,420 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Manuscript length
- ≤ 6,000 words
- Reference style
- Vancouver
Article types accepted11
- case reportCase ReportLength not stated
- case reportsCase Reports Description: The format of the report should be as follows:Length not stated
- editorialThe acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated…Length not stated
- editorialsEditorials Description: Brief comments written by the editor(s) of the journal or by guest editor(s) of Special Features based on the contents of the current is…Length not stated
- news and commentaryNews and Commentary By editor invitation onlyLength not stated
- original articleOriginal ArticleLength not stated
- reviewReviewLength not stated
- reviewsReviews Description: Reviews cover a focused area in the advancing fields of biomedical research and provide a balanced view of current research that can be und…Length not stated
- short communicationShort CommunicationLength not stated
- short communicationsShort CommunicationsLength not stated
- theoretical articlesTheoretical Articles Description: Theoretical articles posit a hypothesis about a mechanism related to immunity or disease, along with its implications and sugg…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- Authorship Authorship
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors will be asked to provide a Conflict of Interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all Co-Authors to confirm agreement with the final statement.
Source ↗Publisher website ·- Data availability
Data sharing encouraged but not mandatory Model summary
Clinical & Translational Immunology expects data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters.
Source ↗Publisher website ·- Publication ethics Publication Ethics
COPE member Model summary
This journal is a member of the Committee on Publication Ethics (COPE). Note that this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.In cases where scientific misconduct is suspected, Clinical & Translati…
Source ↗Publisher website ·- Open access
Open Access Model summary
open access, fully peer-reviewed journal
Source ↗Publisher website ·- Peer review
Single-anonymous peer review Model summary
Except where otherwise stated, manuscripts are single-anonymous peer reviewed.
Source ↗Publisher website ·- Preprints
Preprints allowed Model summary
Clinical & Translational Immunology will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the Abstract. If the trial is not registered, or was registered retrospectivel…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2050-0068
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical & Translational Immunology
What CAS zone is Clinical & Translational Immunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical & Translational Immunology is in Zone 3 of Medicine, and in Zone 3 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical & Translational Immunology?
The latest impact factor listed by LetPub is 3.39; CiteScore 7.2, h-index 76.
How long does peer review take at Clinical & Translational Immunology?
Based on the dates recorded on 91 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 136 days (interquartile range 93–207 days); authors report an average review time of about 13 weeks; the journal's website gives an acceptance rate of 20% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical & Translational Immunology?
According to the journal's author guidelines: Manuscript length: ≤ 6,000 words; Reference style: Vancouver. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical & Translational Immunology based?
Of the 32 board members whose country the journal's board page names, 3 (about 9%) are in mainland China; the countries named most often are Australia (23), Mainland China (3) and New Zealand (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical & Translational Immunology?
According to LetPub and DOAJ records, Clinical & Translational Immunology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, PubMed and Embase; that list has not been checked against each database.
Is Clinical & Translational Immunology open access, and what is the APC?
Clinical & Translational Immunology is a fully open-access journal. APC about USD 3,380.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .